|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Ticlopidine#Adult Indications and Dosage]] |
| {{Ticlopidine}}
| |
| {{CMG}}; {{AE}} {{AZ}}
| |
|
| |
|
| ==Indications And Usage==
| | [[Category: Cardiovascular Drugs]] |
| Ticlopidine Hydrochloride Tablets, USP are indicated:
| | [[Category: Drug]] |
| | | [[Category:Antiplatelet drugs]] |
| :*Reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced [[stroke]] precursors, and in patients who have had a completed thrombotic stroke. Because ticlopidine is associated with a risk of life-threatening blood dyscrasias including thrombotic thrombocytopenic purpura (TTP), neutropenia/agranulocytosis and aplastic anemia (see BOXED WARNING and WARNINGS), ticlopidine should be reserved for patients who are intolerant or allergic to aspirin therapy or who have failed aspirin therapy.
| |
| :*Adjunctive therapy with aspirin to reduce the incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation (see CLINICAL TRIALS).<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TICLOPIDINE HYDROCHLORIDE TABLET, FILM COATED [APOTEX CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=707127cb-cdcd-81b0-274d-3c11fefa6824 | publisher = | date = | accessdate = }}</ref> | |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Drugs]] | |